Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Holding CATX?
Track your performance easily
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.20 - $19.05
Previous Close$13.35
Volume350.51K
Average Volume (3M)908.79K
Market Cap
$931.18M
Enterprise Value$611.17M
Total Cash (Recent Filing)$292.87M
Total Debt (Recent Filing)$3.88M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 12, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,430,000
10 Day Avg. Volume1,020,394
30 Day Avg. Volume908,793
Standard Deviation0.46
R-Squared0.03
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)2.64
Price to Sales (P/S)1055.43
Price to Cash Flow (P/CF)-25.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue103.17
Enterprise Value/Gross Profit426.20
Enterprise Value/Ebitda-17.57
Forecast
1Y Price Target
$22.60Price Target Upside63.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Perspective Therapeutics News
PremiumCompany Announcements
Mark Austin Steps Down from Executive Roles at Perspective Therapeutics
PremiumCompany Announcements
Perspective Therapeutics Announces Executive Financial Reorganization
Bulls Say, Bears Say
Bulls Say
Efficacy ResultsPositive interim data from the open-label, single-arm, IST of Pb-212-VMT-α-NET for the treatment of pre-treated and progressive metastatic neuroendocrine tumors.
Financial OutlookThe current cash position is expected to fund operations through mid-2026.
Manufacturing ExpansionManufacturing sites have now been purchased in/near Somerset (New Jersey), Houston (Texas), and Chicago (Illinois) and are being brought online to support production of assets.
Bears Say
Clinical TrialsInsufficient data from AlphaMedix's Ph. II trial in RLT-naive NET poses challenges for accelerated approval.
Safety ConcernsThe increased Grade 3/4 lymphopenia rate is alarming, especially in RLT-naive patients.
Stock PerformanceCATX stock was down 27% from the recent 52-week high.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.20 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.026.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,427,666 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went up 5.707%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Deerfield Management Company, LP. It holds Perspective Therapeutics’s shares valued at 28M.
---
Perspective Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.60 (63.65% Upside)
$22.60 (63.65% Upside)
Hedge Fund Trend
Increased
By 19.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
317.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
221.21%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$22.60
▲(63.65% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+142.29%
reiterated a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +142.29% per trade.
---